Evidence map›Paper›PMID 32118264›Full record

ReviewIntegrative biology : quantitative biosciences from nano to macro2020

Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro.

Molly M Morgan, Linda A Schuler, Jordan C Ciciliano, Brian P Johnson, Elaine T Alarid, David J Beebe

Open access · greenAbstract readReview
In one paragraph

Review in Integrative biology : quantitative biosciences from nano to macro, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Engineering complexity in human tissue models of cancer.Advanced drug delivery reviews · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Molly M MorganDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Linda A SchulerDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA.
Jordan C CicilianoDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Brian P JohnsonDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Elaine T AlaridCarbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
David J BeebeDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Molecular & Environmental Toxicology Pre-& Postdoctoral Training ProgramT32ES007015 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI CHRISTOPHER A BRADFIELD · 1985 to 2026
$11.5M
Matrix density promotes pro-tumorigenic hormone actions in breast cancerR01CA179556 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PONIK, SUZANNE MARIE, SCHULER, LINDA A. · 2014 to 2024
$4.9M
An automated high-throughput tissue model for screening metastatic effectorsR01CA186134 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J · 2015 to 2019
$3.1M
Molecular and Cellular Mechanisms of Tumor DevelopmentT32CA157322 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALEXANDER, CAROLINE M · 2011 to 2017
$1.6M
Elucidating AHR signaling interplay in orofacial clefting and endocrine disruption using microplate microfluidicsR00ES028744 · NIEHS · MICHIGAN STATE UNIVERSITY · PI JOHNSON, BRIAN P. · 2020 to 2022
$745k
Elucidating AHR signaling interplay in orofacial clefting and endocrine disruption using microplate microfluidicsK99ES028744 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI JOHNSON, BRIAN P. · 2018 to 2019
$200k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA179556NCI NIH HHS R01 CA186134NCI NIH HHS T32 CA157322NIEHS NIH HHS K99 ES028744NIEHS NIH HHS R00 ES028744NIEHS NIH HHS T32 ES007015
6 · The paper itself

Abstract

Accumulating evidence suggests that our ability to predict chemical effects on breast cancer is limited by a lack of physiologically relevant in vitro models; the typical in vitro breast cancer model consists of the cancer cell and excludes the mammary microenvironment. As the effects of the microenvironment on cancer cell behavior becomes more understood, researchers have called for the integration of the microenvironment into in vitro chemical testing systems. However, given the complexity of the microenvironment and the variety of platforms to choose from, identifying the essential parameters to include in a chemical testing platform is challenging. This review discusses the need for more complex in vitro breast cancer models and outlines different approaches used to model breast cancer in vitro. We provide examples of the microenvironment modulating breast cancer cell responses to chemicals and discuss strategies to help pinpoint what components should be included in a model.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCell Line, TumorDisease ProgressionDrug Screening Assays, AntitumorEpitheliumExtracellular MatrixFemaleHumansInflammationModels, StatisticalNeoplasmsPhenotypeTissue EngineeringTumor MicroenvironmentAntineoplastic Agents3Dbreast cancerdrugsenvironmental chemicalsmicroenvironment

Identifiers

PMID32118264
PMCPMC7060306
OpenAlexW3010627926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.